We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Innovative Platform to Address Need for Fast and Accurate POC Testing for Infectious Diseases

By LabMedica International staff writers
Posted on 22 Sep 2023

Emerging infectious diseases account for over a billion cases of illness each year and are a major cause of death globally. Vector-borne diseases like mosquitoes are especially dangerous, putting over half of the world's population at risk, as per the World Health Organization. Accurate diagnosis is critical for the effective management of infectious diseases, but traditional lab tests often come with drawbacks like high costs, complexity, slow development, and limited global availability. To tackle these issues, a new open point-of-care (POC) platform aims to provide quick and accurate POC testing for emerging and neglected infectious diseases.

Kephera Diagnostics’ (Framingham, MA, USA) MiCRIA Open POC platform aims to fulfill the need for rapid POC testing on a global scale. The platform uses easily produced reagents, allowing for universal accessibility of precise, two-minute POC tests, even in areas lacking resources. Unlike other tests that require disease-specific strips or cartridges, this patent-pending system employs a generic cassette and assay-specific reagents. Furthermore, the assay is based on microfluidic technology rather than membrane-based methods.


Image: The MiCRIA Open POC platform uses reagents that can be made anywhere, by anyone in a basic, standard laboratory (Photo courtesy of Kephera Diagnostics)
Image: The MiCRIA Open POC platform uses reagents that can be made anywhere, by anyone in a basic, standard laboratory (Photo courtesy of Kephera Diagnostics)

The test-specific reagent is derived by an antibody, antigen, or other ligand, and can be quickly mass-produced using standard laboratory equipment. The platform features a compact and economical reader that can be managed through a smartphone or another mobile device to conduct tests as well as interpret and display results. Kephera's MiCRIA Open POC platform has shown to have better sensitivity compared to lateral flow rapid tests and is almost as effective as ELISA tests.

Related Links:
Kephera Diagnostics 


New
Gold Member
ANCA IFA
Kallestad Autoimmune ANCA IFA Complete Kit
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Clostridium Difficile Assay
Revogene C. Difficile
New
Control Material
Blood Culture Identification Control Panel

Latest Molecular Diagnostics News

Non-Invasive Test Detects Up To 42 Solid Tumors and Five Blood Cancers in Blood and Urine Samples

New Quantitative Testing System for Coronavirus Detection Could Also Diagnose Other Viral Illnesses

Single PCR Test Simultaneously Detects 12 Respiratory Viruses in Same Patient Sample



CELLAVISION AB